Today: 8 June 2026
Walmart stock price slips to $123 as cautious outlook and HSBC downgrade keep WMT on the back foot
21 February 2026
2 mins read

Walmart stock price slips to $123 as cautious outlook and HSBC downgrade keep WMT on the back foot

New York, Feb 20, 2026, 18:39 EST — After-hours

  • Walmart stock dropped roughly 1.5% to $122.99 late Friday, extending a two-day decline following its earnings report.
  • HSBC downgraded Walmart to “hold,” citing valuation concerns following the retailer’s cautious FY27 guidance.
  • Walmart is projecting adjusted EPS for FY27 to land between $2.75 and $2.85, and the retailer also rolled out a fresh $30 billion buyback authorization.

Walmart shares dropped 1.5% to $122.99 in after-hours trading Friday, with the stock sliding further after the company flagged a cautious profit outlook. That was compounded by a new analyst downgrade.

This shift is notable: Walmart often serves as an early signal for the state of U.S. household finances. So when the retail giant turns more cautious, investors start to wonder if consumers are opting for cheaper options or just pulling back altogether—and what that could mean for retail margins.

The stock caught attention as the broader market ended up, lifted by a Supreme Court ruling scrapping a major set of Trump-era tariffs. That move dialed back trade-policy uncertainty. Investors, for their part, kept sorting through softer growth numbers alongside persisting signs of inflation.

HSBC cut Walmart to a “hold” from “buy” but bumped its price target up to $131, compared with $122 previously, arguing that the stock’s premium limits upside if anything goes wrong. “It is hard to see a marked deterioration in the trading environment,” analysts Joe Thomas and Guilherme Domingues wrote, although they noted Walmart’s valuation gap with Costco is narrowing. Investing.com

Walmart reported Thursday that fourth-quarter revenue climbed 5.6% to $190.7 billion, with adjusted earnings per share coming in at $0.74, according to an SEC filing. Looking ahead, the retailer projects adjusted EPS for fiscal 2027 between $2.75 and $2.85. Net sales are expected to grow 3.5% to 4.5% in constant currency, not factoring in exchange-rate changes. The company also authorized a fresh $30 billion share buyback. The “adjusted” figures strip out certain items, such as fluctuations in equity and other investments, the filing added. SEC

CEO John Furner told analysts that lower-income customers are still feeling squeezed. For shoppers making under $50,000, “wallets are stretched,” he said. Still, U.S. comparable sales—excluding fuel—were up 4.6%, and online sales in the U.S. jumped 27%. David Silverman, analyst at Fitch, noted that Walmart’s size lets it “capitalize on e-commerce growth,” as competitors like Target have had trouble getting shoppers back for higher-priced items. Reuters

The situation can change fast. Should hiring soften or costs spike anew—tariffs, shipping, wages—Walmart’s reputation for low prices might not be enough to cushion its discretionary sales. In that case, it’s the stock’s valuation investors need to watch, not its upside.

Walmart’s board signed off on a 5% bump to the annual dividend, now set at $0.99 per share for fiscal 2027, with quarterly payouts of $0.2475. “We’re proud to be increasing our annual dividend for the 53rd consecutive year,” said CFO John David Rainey. March 20 is the next record date, and shareholders get paid April 6. Walmart News

Next week, the market focus will be on whether investors view the guidance as deliberately conservative or as a genuine warning on consumer demand. Buybacks are also on the radar, with traders watching to see how soon they start moving the tape. Macro-exposed retail stocks have another test coming up with the Federal Reserve’s policy meeting on March 17–18.

Stock Market Today

  • KOSPI Index Plunges Amid Global Market Turmoil
    June 8, 2026, 9:07 AM EDT. South Korea's KOSPI experienced a sharp crash triggered by margin stress in chip stocks and a circuit breaker trading halt. The selloff in global markets was fueled by a strong U.S. jobs report signaling prolonged high interest rates, fears of a yen carry trade unwind amid Bank of Japan tightening, and a crypto selloff following Zcash network vulnerabilities. U.S. futures rebounded slightly as chip stocks recovered, with investors focused on upcoming inflation data and SpaceX's anticipated IPO. Rising Middle East tensions keep oil prices elevated near $94 per barrel. The volatile market reflects growing concerns over liquidity absorption from the SpaceX listing, geopolitical risks, and tightening monetary policies globally.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Broadcom stock slips after-hours: AVGO price, new 6G BroadPeak chip and VMware partner shake-up in focus
Previous Story

Broadcom stock slips after-hours: AVGO price, new 6G BroadPeak chip and VMware partner shake-up in focus

TSMC stock 2330.TW back in focus as Taiwan reopens; Nvidia earnings loom
Next Story

TSMC stock 2330.TW back in focus as Taiwan reopens; Nvidia earnings loom

Go toTop